New Agents for the Treatment of Advanced Bladder Cancer

Philippa J. Cheetham, Daniel P. Petrylak

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Despite recent advances in the management of a wide variety of solid tumors, the outcomes for patients with metastatic urothelial carcinoma (MUC) remain extremely poor. Cisplatin-based combination chemotherapy remains the standard of care for first-line systemic treatment of MUC, and for more than 20 years there have been no other US Food and Drug Administration-approved treatment options available for these patients. Finally there appears to be hope on the horizon, with an ever-increasing number of precisely targeted agents being developed for use in MUC, resulting in improved survival rates. These targeted agents have now entered the cancer treatment arena, a direct result of a greater understanding of the genetic background of MUC. In this review article, we summarize the current state of development of these targeted agents, used either alone or in combination with traditional chemotherapy in MUC. Our discussion focuses on the most promising novel agents, including therapies targeting receptors for fibroblast growth factor and endothelial growth factor; antiangiogenesis agents (bevacizumab); tyrosine kinase inhibitors (cabozantinib); and immune checkpoint inhibitors that target proteins in the immune checkpoint-regulation pathway (anti-programmed death 1 and anti-programmed death ligand 1).

Original languageEnglish
Pages (from-to)571-9, 588
Issue number6
StatePublished - 1 Jun 2016


Dive into the research topics of 'New Agents for the Treatment of Advanced Bladder Cancer'. Together they form a unique fingerprint.

Cite this